Rights Issue April-May 2019
Raising up to 100 million SEK during April and May 2019.
Invest in Oncology Venture now
- and get warrants without payment
Right now Oncology Venture is issuing new shares to fund the further development of our pipeline of seven precision medicine candidates.
For every two subscription rights (traded as ‘Oncology Venture UR’, the holder will be entitled to subscribe for one ‘offer unit’.
Each unit consists of one new share, with one warrant attached which confers the right to subscribe for a share at an exercise price of SEK 7.50.
New shares are subscribed against cash payment of SEK 4.00. Investor warrants are subscribed without payment.
Oncology Venture's ongoing clinical studies
Dovitinib (a multi-tyrosine kinase inhibitor) – Breast Cancer
LiPlaCis® – Breast and Prostate Cancer
Irofulven – Prostate Cancer
APO010 – Multiple Myeloma
2X-111 (liposomal doxorubicin) - Metastatic Breast Cancer
2X-121 (PARP-inhibitor) – Breast Cancer
ongoing and in preparation for Ovarian Cancer
CEO Peter Buhl presents the rights issue at BioStock Live
BioStock Live was recorded on 29 April 2019 in Stockholm, Sweden.
Watch Oncology Venture's CEO Peter Buhl Jensen present at BioStock Live.
Planned clinical studies
Irofulven – Ovarian Cancer
APO010 – Breast Cancer
2X-111 – Glioblastoma (an aggressive
cancer beginning within the brain)
2X-121 (PARP-inhibitor) – Ovarian Cancer
Ixabepilone (Ixemp(Ixempra®) – Metastatic Breast Cancer.
Upcoming Investor Presentations
We will present at several events before the subscription period ends.
Location: Malmöhusvägen 1, Malmö, Sweden
Location: Kungsgatan 33, Stockholm, Sweden
Event hosted by Dansk Aktionærforening
Location: Kolding Uddannelsescenter, Ågade 27, 6000 Kolding Denmark
Location: Søhuset Konferencecenter, Venlighedsvej 10, 2970 Hørsholm
Location: Birger Jarlsgatan 57 A, Stockholm